From MarketBeat:



Cencora (NYSE: COR) was recently downgraded from a “strong-buy” to a “buy” rating by equities researchers at StockNews.com. Other equities research analysts have also commented on the stock, with three rating it as hold and nine issuing a buy rating. The company has a consensus rating of “Moderate Buy” and a consensus target price of $198.67. Shares of COR opened at $203.04 on Friday and have a 50 day moving average of $196.57. Cencora last announced quarterly earnings that exceeded consensus estimates, and company insiders have sold a significant number of shares in the last 90 days. Several hedge funds have also made changes to their positions with Cencora. The company’s business includes distributing pharmaceutical products and related services to various healthcare providers. While Cencora currently has a “Moderate Buy” rating among analysts, top-rated analysts are recommending five other stocks as better buys. Additionally, MarketBeat has released a list of 20 stocks that top analysts are advising against as potential investments.



Original: Cencora (NYSE:COR) Lowered to “Buy” at StockNews.com